GNPX Genprex, Inc.
Price Chart
Executive Summary
Genprex announced that its research collaborators' abstract was published at the 2026 ASCO Annual Meeting, detailing positive clinical data on predictive biomarkers (Trop-2 and PTEN) for its lead drug candidate Reqorsa Gene Therapy in lung cancer. The data from 18 patients showed that high Trop-2 and low PTEN levels correlated with prolonged progression-free survival in NSCLC, but not in SCLC. This is an early-stage scientific update with no financial data or near-term catalyst.
Actionable Insight
This is a scientific update with no immediate stock-moving catalyst. Monitor for future clinical trial results (Acclaim-1, -2, -3) and any biomarker-driven patient selection strategy updates. The tiny patient sample (n=18) limits statistical power.
Key Facts
- Abstract published at 2026 ASCO Annual Meeting titled 'Predictive biomarkers for PFS in patients receiving quaratusugene ozeplasmid'
- Data from 18 patients across three Acclaim clinical trials (Acclaim-1, Acclaim-2, Acclaim-3)
- In NSCLC patients (n=7), Trop-2 H-scores above 100 correlated with prolonged PFS (p=0.05) and PTEN H-scores below 100 correlated with prolonged PFS (p=0.03)
- In SCLC patients (n=11), Trop-2 H-scores were universally low and non-evaluable; PTEN did not correlate with PFS (p=0.53)
- High (3+) Trop-2 expression will be investigated further as a potential biomarker for REQORSA
- No financial figures, guidance, or regulatory milestones disclosed
Financial Impact
No financial impact disclosed; pre-revenue clinical-stage biotech with $7M market cap
Risk Factors
- Very small sample size (18 patients) limits reliability of biomarker correlations
- Biomarker findings are exploratory and require validation in larger trials
- No timeline for next clinical data readout or regulatory submission
- Company faces going concern risk per forward-looking statements in filing
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-018318 |
| Document: 0001437749-26-018318-index-headers.html | 0001437749-26-018318 |
| Document: 0001437749-26-018318-index.html | 0001437749-26-018318 |
| Document: 0001437749-26-018318.txt | 0001437749-26-018318 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
17d ago
|
8-K
| $0.7720 $0.7350 | ▼ −4.79% | ▼ −6.01% | $0.6400 (−17.10%) |
|
May 14, 2026
29d ago
|
8-K
| $0.8610 $0.8150 | ▼ −5.34% | ▼ −4.62% | $0.6400 (−25.67%) |
|
Apr 28, 2026
6w ago
|
8-K
| $0.9250 $0.9390 | ▲ +1.51% | ▼ −0.18% | $0.6400 (−30.81%) |
|
Apr 21, 2026
7w ago
|
8-K
| $1.09 $0.9250 | ▼ −15.14% | ▼ −16.22% | $0.6400 (−41.28%) |
|
Mar 18, 2026
12w ago
|
8-K
| $2.01 $1.94 | ▼ −3.48% | ▼ −2.77% | $0.6400 (−68.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access